LMNGF Stock Price, News & Analysis

LMNGF

Company Description

LMNGF (OTC: LMNGF) is a publicly traded company. The company has a market capitalization of $6.5M.

This page provides a comprehensive overview of LMNGF stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

Performance 1 year

$6.5M

Market Cap

0.0

Shares outstanding

Latest News

View All

June 15, 2022

—

Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development

clinical trial

June 8, 2022

—

Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study

clinical trial

June 3, 2022

—

BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program

May 2, 2022

—

International Patent Application Filed for Cervical Cancer Vaccine

April 25, 2022

—

BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction

March 17, 2022

—

BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University

LMNGF has 10 recent news articles. Key topics include clinical trial, private placement, conferences, covid-19. View all LMNGF news →

SEC Filings

View All

No SEC filings available for LMNGF.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

Frequently Asked Questions

What is the market cap of LMNGF (LMNGF)?

The market cap of LMNGF (LMNGF) is approximately 6.5M. Learn more about what market capitalization means .